Scientific co-founder, Executive Vice President, and Chief Scientific Officer of Incysus
As a transplant immunologist with 27 years’ experience in clinical-translational
immunotherapy research, he is responsible for first describing the association between relapse-free
survival and homeostatic γδT cell recovery in patients with high-risk leukemia following haploidentical
bone marrow transplant. While at the University of Alabama at Birmingham, Dr. Lamb developed the
scientific support for chemotherapy resistant γδT cell-based immunotherapy for high-grade brain
tumors that that has become the foundation of our clinical programs. Dr. Lamb currently leads
clinical, translational, and manufacturing strategy and operations for Incysus Therapeutics.